Medtronic plc
MDT
NYSE80.89
Medtronic plc
NYSE:MDT
RECENT
PRICE
80.89
P/E
RATIO
21.02
(PEG:0.53)
P/E RATIO
RELATIVE
TO S&P
1.05
DIV
YLD
2.54%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.76 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 09/22:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Fiscal year
10.70
2.44
1.99
0.44
11.95
1.97
2.55
0.50
13.06
1.94
2.88
0.75
14.30
2.80
3.16
0.82
14.79
2.87
2.96
0.90
15.36
3.43
3.77
0.97
16.28
3.40
4.34
1.04
16.97
3.06
4.55
1.11
18.49
2.44
3.95
1.22
20.45
2.51
2.96
1.52
21.55
2.92
4.08
1.72
22.08
2.29
2.67
1.84
22.70
3.44
4.36
2.00
21.57
3.57
4.49
2.16
22.39
2.68
3.63
2.32
23.60
3.75
4.45
2.52
23.20
3.88
4.27
2.57
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.60
9.55
0.54
10.20
0.59
11.50
0.57
13.22
0.51
14.82
0.47
16.24
0.45
18.32
0.40
19.40
0.52
48.59
0.74
36.93
0.91
36.47
0.79
37.38
0.84
37.20
0.90
37.84
1.01
38.24
1.02
39.15
1.06
39.16
CAPEX per share
Book Value per share
1,150
1,131
1,118
1,106
1,077
1,054
1,019
1,002
1,096
1,410
1,379
1,357
1,346
1,341
1,345
1,342
1,339
Comm.Shares outs.(m)
21.2
1.2
0.8%
23.7
1.1
1.1%
18.0
0.3
2.2%
13.9
0.7
2.1%
12.9
0.8
2.4%
11.6
0.8
2.4%
15.1
0.9
2.0%
20.6
1.1
1.8%
30.4
1.5
1.6%
31.9
1.4
1.9%
27.8
1.2
2.1%
38.4
1.5
2.1%
28.7
1.2
2.0%
28.6
0.8
2.1%
45.3
1.5
1.9%
26.3
1.3
2.6%
21.0
1.0
2.5%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (29/7/22 | Q1)
Total liabilities
$37,071 m.
Total assets
$89,914 m.
Long-term debt
$17,481 m.
Cash and equiv.
$2,140 m.
Goodwill $40,324 m.
Retained earnings $30,276 m.
Common stock 1,329 m. shares
Market Capitalisation
$108,100 m. (as of 27/9/22)
16,184
29.9%
16,590
28.8%
17,005
28.3%
20,261
18.6%
28,833
18.4%
29,710
17.9%
29,953
22.2%
30,557
20.5%
28,913
16.6%
30,117
14.9%
31,686
18.2%
31,070
19.3%
Revenue (m)
Operating margin
833
3,617
819
3,467
850
3,065
1,306
2,675
2,820
3,538
2,917
4,028
2,644
3,104
2,659
4,631
2,663
4,789
2,702
3,606
2,707
5,039
2,704
5,205
Depreciation (m)
Net profit (m)
17.6%
22.3%
18.4%
20.9%
17.3%
18.0%
23.3%
13.2%
18.4%
12.3%
12.6%
13.6%
45.5%
10.4%
10.5%
15.2%
(17.0)%
16.6%
6.8%
12.0%
8.3%
15.9%
9.0%
16.7%
Income tax rate
Net profit margin
3,658
7,359
17,113
13,902
9,408
18,671
15,651
10,120
19,443
21,671
33,752
53,230
16,435
30,109
52,063
10,609
25,921
50,294
12,896
23,699
50,720
13,495
24,486
50,091
11,665
22,021
50,737
14,039
26,378
51,428
10,665
20,372
52,551
8,086
17,481
52,672
Working capital (m)
Long-term debt (m)
Equity (m)
14.2%
14.2%
21.1%
12.2%
13.3%
18.6%
10.4%
10.8%
15.8%
3.3%
3.9%
5.0%
5.0%
5.7%
6.8%
5.8%
5.7%
8.0%
4.6%
7.5%
6.1%
7.3%
7.4%
9.2%
7.6%
5.7%
9.4%
5.3%
5.2%
7.0%
7.1%
6.7%
9.6%
7.6%
7.0%
9.9%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
10,948
10,401
10,522
Receivables
4,645
5,462
5,551
Inventory
4,229
4,313
4,616
Other
2,209
1,956
2,319
Current assets
22,031
22,548
23,059
Acc. Payable
1,996
2,106
2,276
Debt due
2,776
11
3,742
Other
5,594
6,392
6,376
Current liab.
10,366
8,509
12,394
71.8%
59.6%
69.6%
46.0%
63.6%
51.8%
50.0%
60.2%
39.5%
107.3%
41.0%
97.6%
19.7%
117.9%
41.8%
77.9%
39.6%
59.1%
13.5%
67.5%
33.2%
56.6%
34.0%
93.5%
Plowback ratio
Div.&Repurch. to FCF
Medtronic plc (IE) started trading on March 1, 1980 (cik: 0001613103), operates in the Healthcare sector (Medical Devices industry), has 95,000 full-time employees, and is led by Mr. Omar Ishrak. Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
1.50%
8.20%
Cash flow
17.11%
6.88%
Earnings
16.91%
7.39%
Dividends
7.92%
14.81%
Book value
0.90%
19.64%
Insider trading
Type
Shares
Date
Wall Brett A.
Award
59,433
08/01/22
Wall Brett A.
Award
18,802
08/01/22
Wall Brett A.
Award
7,521
08/01/22
Smith Gregory L
Award
44,151
08/01/22
Smith Gregory L
Award
13,967
08/01/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2021
6,507
7,647
7,775
8,188
30,117
2022
7,987
7,847
7,763
8,089
31,686
2023
7,371
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2021
0.36
0.37
0.94
1.01
2.68
2022
0.57
0.98
1.10
1.11
3.75
2023
0.70
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2021
0.58
0.58
0.58
0.58
2.32
2022
0.63
0.63
0.63
0.63
2.52
2023
0.68
- -
- -
- -
- -
08/24/2021
Palo Alto Networks, CrowdStrike, Pinduoduo: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
06/03/2021
Medtronic to Stop Selling Implantable Heart Pump Over Safety Concerns
The Wall Street Journal - Read more...
09/30/2020
Justice Department Opens Ventilator Antitrust Probe Focused on Medtronic
The Wall Street Journal - Read more...